Department of Hematology, Nanjing Medical University, Wuxi, Jiangsu Province, China.
Leuk Lymphoma. 2012 Jun;53(6):1183-7. doi: 10.3109/10428194.2011.641179. Epub 2012 Jan 3.
The C3435T (Ile1142Ile) polymorphism of the multidrug resistance gene (MDR1) has been implicated in leukemia risk, but the reported results are inconsistent. Here we performed a meta-analysis to evaluate the association between C3435T polymorphism and the risk of leukemia using all case-control studies published before June 2011 according to PubMed. A total of 10 case-control studies were included in this analysis. We found that variant genotypes of C3435T (CT/TT) were significantly associated with an increased risk of leukemia (CT/TT vs. CC: odds ratio [OR] = 1.29; 95% confidence interval [CI] = 1.11-1.50, p = 0.284 for heterogeneity test). Additionally, the association was more significant in chronic leukemia (specifically B-cell chronic lymphocytic leukemia [B-CLL]) (OR = 1.94; 95% CI = 1.32-2.85, p = 0.648 for heterogeneity test) than in acute leukemia (OR = 1.19; 95% CI = 1.01-1.40, p = 0.616 for heterogeneity test), p = 0.021 for heterogeneity test between groups. These findings provide further evidence that the MDR1 C3435T variant may modify the susceptibility to leukemia.
多药耐药基因(MDR1)的 C3435T(Ile1142Ile)多态性与白血病风险相关,但报道的结果并不一致。在这里,我们根据 PubMed 数据库,对截至 2011 年 6 月之前发表的所有病例对照研究进行了荟萃分析,以评估 C3435T 多态性与白血病风险之间的相关性。共有 10 项病例对照研究纳入了本分析。我们发现,C3435T(CT/TT)变异基因型与白血病风险增加显著相关(CT/TT 与 CC:比值比 [OR] = 1.29;95%置信区间 [CI] = 1.11-1.50,p = 0.284 用于异质性检验)。此外,这种相关性在慢性白血病(特别是 B 细胞慢性淋巴细胞白血病 [B-CLL])中更为显著(OR = 1.94;95% CI = 1.32-2.85,p = 0.648 用于异质性检验),而在急性白血病中不显著(OR = 1.19;95% CI = 1.01-1.40,p = 0.616 用于异质性检验),p = 0.021 用于组间异质性检验。这些发现进一步证明,MDR1 C3435T 变异可能会改变白血病的易感性。